ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae.
Michael R JacobsCaryn E GoodAndrea M HujerAyman M AbdelhamedDaniel D RhoadsKristine M HujerSusan D RudinT Nicholas DomitrovicLynn E ConnollyKevin M KrauseRobin PatelCesar A AriasBarry N KreiswirthLaura J RojasRoshan D'SouzaRichard C WhiteLauren M BrinkacKevin NguyenIndresh SinghDerrick E FoutsDavid Van DuinRobert A Bonomonull nullPublished in: Antimicrobial agents and chemotherapy (2020)
Plazomicin was tested against 697 recently acquired carbapenem-resistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.